Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

11.1%

2 terminated out of 18 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results60% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (1)
P 1 (3)
P 2 (10)

Trial Status

Recruiting5
Unknown3
Completed3
Terminated2
Withdrawn2
Active Not Recruiting2

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT06839456Phase 1Recruiting

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT04644016Phase 2Recruiting

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

NCT04211714Phase 1Active Not Recruiting

Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure

NCT03579875Phase 2Recruiting

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT07227155Not Yet Recruiting

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

NCT03622788Phase 1Active Not Recruiting

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

NCT04232085Phase 2Recruiting

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT01019876Phase 2CompletedPrimary

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

NCT06250595Recruiting

European Rare Blood Disorders Platform (ENROL)

NCT02833805Phase 2Completed

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

NCT00968864Phase 2Terminated

T-cell Depleted Alternative Donor Transplantation

NCT01200017Unknown

Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

NCT03249129WithdrawnPrimary

Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma

NCT01856582Phase 2Terminated

CD34+ Stem Cell Infusion to Augment Graft Function

NCT01049854Phase 2Completed

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

NCT03086252Not ApplicableWithdrawn

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

NCT01642979Phase 2Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria

NCT01760096Phase 2Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Showing all 18 trials

Research Network

Activity Timeline